Johnson & Johnson Behind Schedule With Covid Vaccine Production

JOHNSON & JOHNSON are apparently behind schedule with the production of its Covid vaccine, according to The New York Times.

Johnson & Johnson is apparently behind schedule with the production of its Covid-19 vaccine. The New York Times is saying that US government officials had been told that they were up to two months behind the original schedule and that they would not catch up until the end of April at the earliest when it agreed to deliver more than 60 million doses.

Earlier this week, a Johnson & Johnson executive said the company was in the process of securing about one billion doses of the vaccine by the end of 2021 and was in the final stages of analysing large-scale clinical trial data.

However, the report also cites the senior production advisor for Operation Warp Speed, saying that the company may be able to catch up on initial production targets by March. The pharmaceutical company’s vaccine, which only requires a single dose, has not yet been approved, but the clinical phase III study is in the final phase. According to the newspaper, the results of the study could be published in two weeks.

In August, Johnson & Johnson signed a 1 billion dollar deal with the US government to supply 100 million doses of its vaccine by mid-2021.

In December, J&J announced that it was awaiting preliminary results from the final phase clinical trial in late January.

Thank you for taking the time to read this news article “Johnson & Johnson Behind Schedule With Covid Vaccine Production”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.